You are here: All Products  > CASI Acquires Global Rights To CD19 T-Cell Therapy; Will Make $11.6 Million Investment

CASI Acquires Global Rights To CD19 T-Cell Therapy; Will Make $11.6 Million Investment

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products